Currently, there is an ongoing clinical trial with a dual PI3K/mTOR inhibitor, gedatolisib (PF-05212384), in combination with a CDK4/6 inhibitor, palbociclib (PD-0332991), for patients with advanced solid tumors including PCa. Here, MTOR is linked to posterior cortical atrophy.